MorphoSys AG announces Roche plans to initiate a Phase III programme with gantenerumab in patients with prodromal to mild Alzheimer's disease.
MorphoSys AG announced that its partner Roche plans to initiate a new pivotal phase III program for gantenerumab in patients with prodromal to mild Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against beta amyloid generated by MorphoSys using its proprietary HuCAL antibody technology. MorphoSys was informed that Roche intends to commence preparations for two studies and would expect to start the program later this year. Further information including details of the trials are not yet available.
Comment: Gantenerumab experienced a Phase III failure in 2014 missing both primary and secondary endpoints.A new liquid formulation of the drug at a higher dose may progress into Phase III.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.